Filing Flows › Health Care › Ideaya Biosciences (IDYA)
Ideaya Biosciences (IDYA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · Ideaya Biosciences (IDYA) Q3 2026 earnings results →
Q3 2026 Revenue down 95% year over year to $10.2M
Ideaya Biosciences made $10.2M in Q3 2026 (-95% Y/Y). Operating margin n/m, net loss $126M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $10.2M in Q3 2026, down 95% year over year and up 16% from the previous quarter.
Operating costs exceeded revenue by $137.6M, an operating margin of -1343.8%. Total costs grew 49% against a revenue fall of 95%. The fastest-growing cost line was General & admin (+60%). The quarter ended with a net loss of $125.7M, wider than the previous quarter's $112.5M loss.
Operating cash flow was −$93.5M. Non-cash charges added back $614K of depreciation and amortization and $17.7M of share-based compensation. Working capital and other items added $13.9M. Capital expenditures of $273K exceeded it, leaving free cash flow of −$93.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 3, 2026 | $10.2M | -95% | n/m | −$126M | −$93.5M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $8.9M | — | n/m | −$112M | −$88.2M |
| Q1 2026 | 10-Q | May 5, 2026 | $6.6M | — | n/m | −$98.5M | −$75.2M |
| Q4 2025 | 10-K | Feb 17, 2026 | $10.9M | +55% | -869.5% | −$83.3M | −$90.5M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $208M | — | 52.2% | $119M | $142M |
| Q4 2024 | 10-K | Feb 18, 2025 | $7.0M | +78% | n/m | −$130M | −$122M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Ideaya Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
In its own words, from its 8-K, filed Aug 4, 2026.
Ideaya Biosciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -95% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IDYA Ideaya Biosciences | Q3 2026 | $10.2M | -95% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Ideaya Biosciences 10-Q on SEC EDGAR · CIK 1676725 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns IDYA and who is buying
More on IDYA
- How Ideaya Biosciences makes money: revenue by segment
- Ideaya Biosciences next earnings date and what analysts expect
- Ideaya Biosciences stock forecast, price target and fair value
- Who owns Ideaya Biosciences stock: holders, funds and Congress trades
- Ideaya Biosciences guidance and outlook
- Is Ideaya Biosciences a takeover target? LBO and rumors
- Ideaya Biosciences recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q4 2024 results